Acute Myeloid Leukemia | Striving for Consensus on the Management of Secondary Acute Myeloid Leukemia

A clinical investigator think tank and enduring multimedia activity with Drs Naval Daver, Stephen Strickland, Geoffrey Uy and Eunice Wang, including the following topics: Introduction to therapy-related Acute Myeloid Leukemia (AML) (0:00) Treatment of AML evolving from prior MDS (12:27) Treatment of secondary AML in a patient ineligible for intensive therapy (29:41) Treatment for a patient with secondary AML with an IDH mutation (40:56) Long-term follow-up of CPX- 351 in patients with secondary AML (46:27) Potential role of venetoclax in combination with intensive chemotherapy regimens (52:54) Treatment for younger patients with secondary AML (58:46) Treatment of secondary AML with a FLT3 mutation (1:03:59) Data with CPX-351 in combination with targeted agents (1:08:30) Refractory disease versus differentiation syndrome from IDH inhibitors (1:19:20) Emerging data with menin inhibitors (1:28:13) Treatment of secondary AML evolving from prior MPN (1:31:52) Treatment of secondary AML with core binding factor (1:53:14) CME information and select publications